Introduction
The helix-loop-helix inhibitor of differentiation and DNA binding (Id1) is well known as an oncogene promoting cell proliferation and cell cycle progression. The role of Id1 is also implicated in the regulation of cell differentiation, senescence, apoptosis, angiogenesis and invasion in a variety of tumors (Ling et al., 2006) . Our previous study has suggested that Id1 was associated with tumor angiogenesis in invasive breast ductal carcinoma cells (Jang et al., 2006) . We reported that Id1 induced expression of vascular endothelial growth factor by promoting the stability and activity of hypoxia-inducible factor-1 a, and thus has a pivotal role in tumor angiogenesis (Kim et al., 2007) . Id1 has also been implicated in cancer cell survival. Our published data showed that Id1 regulated Bax and Bcl-2 family genes to defend cells from anticancer druginduced apoptosis through the p53 and necrosis factorkB pathways . Furthermore, Id1 was found to activate the PI3K/Akt/necrosis factor-kB signaling pathway, which protects cancer cells against apoptosis in esophageal cancer (Li et al., 2007) . Recently, we reported that Id1-modulated Akt activity and its downstream effectors, the Wnt pathway and p27 Kip1 , through p53-mediated PTEN inhibition in human breast cancer (Lee et al., 2009) . More recent studies also show the PI3K/Akt signaling-mediated regulation of cell survival, metastasis and tumorigenicity by Id1 in several cancer cell lines (Li et al., 2009; Lin et al., 2010) . All the evidence suggests that Id1 appears to function partially through activation of the PI3K/Akt signaling pathway, which has critical roles in angiogenesis and antiapoptosis. Several studies have reported that Akt coordinates with epigenetic mechanisms to regulate gene expression. For example, Akt bound with SETDB1, a histone H3 methytransferase, and resulted in gene silencing (Gao et al., 2007) . The PI3K/Akt pathway was also involved in eliminating the repression of necrosis factor-kB transcriptional activity, which is mediated by histone deacetylases-1 (Choi and Jeong, 2005) . These results imply that Id1 may be involved in Akt-mediated epigenetic regulation.
Polycomb group (PcG) proteins, crucial epigenetic gene silencers, have been associated with neoplastic development. PcG proteins are classified into two groups, named polycomb repressive complexes (PRCs) (Levine et al., 2004; Lund and van Lohuizen, 2004) . The PRC2 complex, which consists of EZH2, SUZ12 and EED among others, is known as an initiator of transcription repression through histone H3 tri-methylation at lysine 27 (Cao et al., 2002) . The PRC1 complex, composed of Bmi-1, HPH2, PC3 and RING proteins, is recruited through the recognition of the tri-methylation of H3K27 and mediates histone H2A ubiquitination at lysine 119 to maintain the transcription repression (Wang et al., 2004) . RING1b is an ubiquitin E3 ligase whose catalytic activity is enhanced by binding with a RING finger protein, Bmi-1, which is one of the core subunits of the PRC1 complex (Buchwald et al., 2006; Li et al., 2006) . In particular, Bmi-1 is very critical for RING1b E3 ligase activity-mediated gene silencing, because knockdown of Bmi-1 led to loss of histone H2A ubiquitination and upregulation of its target, HoxC5 genes (Wei et al., 2006) . The PRC1 complex has also been shown to function as an E3 ubiquitin ligase for degradation of target protein, such as geminin, which prevented DNA replication and maintained the undifferentiated cell state (Saxena and Dutta, 2005; Seo et al., 2005; Ohtsubo et al., 2008) . Moreover, a recent study has shown that RING1b protein also could be selfubiquitinated and this is crucial for its H2A ubiquitination activity (Zaaroor-Regev et al., 2010) . Another RING finger protein Mel-18, a homolog of Bmi-1, was reported to be unable to stimulate E3 ligase activity even if it binds with RING1b (Cao et al., 2005) . However, a recent study reported that Mel-18 mediated the ubiquitination of H2A lysine 119 by targeting Mel-18/ RING1b complex to chromatin, which depended on the phosphorylation state of Mel-18 (Elderkin et al., 2007) . Interestingly, several studies have suggested that Mel-18 acted as a negative regulator of Bmi-1. Lee et al. (2008) showed that Mel-18 functioned as a tumor suppressor by repressing Bmi-1 expression and Akt activity in breast cancer cells. Another study indicated that Mel-18 repressed Bmi-1 transcription via downregulation of c-Myc, which resulted in accelerated senescence in normal human cells (Guo et al., 2007) .
In this study, we investigated the possible role of Id1 in epigenetic transcriptional regulation in breast cancer. We examined the effect of Id1 on PcG proteins and found that Id1 regulated the expression of Mel-18 and Bmi-1, both of which belong to PRC1. We report here that Id1 enhanced E3 ligase activity of RING1b through the PI3K/Akt signaling pathway and consequently resulted in the accumulation of histone H2A ubiquitination and degradation of geminin via the proteasomal pathway. Both Bmi-1 and geminin, which were reported to be regulated by Id1, have been suggested to have important roles in supporting stem cells; it is possible that Id1 may be involved in the regulation of malignant human stem cells. (Figures 1a and b, left panels) . Interestingly, Id1 ectopic expression or knockdown only had an effect on Bmi-1 but not Mel-18 at the mRNA level as assessed by reverse transcriptase-PCR (Figures 1a and b , right panels). Together, these data suggest that Id1 has an effect on the expression of PRC1 but not PRC2 members in breast cancer cells.
Results

Id1
Id1 induces Akt-mediated Mel-18 downregulation As shown in Figure 1 , Mel-18 was negatively regulated by Id1 at a post-trancriptional level; we next pursued investigation into the mechanism by which Mel-18 was modulated by Id1. We have found that Mel-18 expression was increased upon PI3K inhibitor LY294002 treatment, which implied the regulation of Mel-18 by the Akt pathway . In our previous study, we also suggested that MCF7 cells stably overexpressing Id1 showed increased phosphorylation of Akt at Ser473, which was associated with activation of the Akt signaling pathway . Therefore, we hypothesized that Id1-induced Mel-18 downregulation was mediated by the Akt pathway. As shown in Figure 2a , Id1 overexpressing MCF7 cells showed increased phosphorylation of Akt at Ser473. Moreover, downregulated expression of Mel-18 by Id1 was significantly recovered after treatment with LY294002 ( Figure 2b ). These results indicate that Id1 induces Akt-mediated Mel-18 downregulation.
Id1 enhances c-Myc and Bmi-1 transcription through inhibition of Mel-18 To ascertain the mechanism whereby Id1 regulated Bmi-1, we first assessed Bmi1 promoter activity that was significantly increased by Id1 as measured by luciferase assay (Figure 3a, lanes 3 and 4) . As c-Myc has been demonstrated to regulate the expression of Bmi-1 through binding to the E-box that was present in the Bmi-1 promoter in breast cancer cell lines (Guo et al., 2007) , we then examined the c-Myc expression and found that both protein and mRNA levels were increased in Id1 overexpressing MCF7 cell lines ( Figure 3a , left panel). To confirm that the regulation of Bmi-1 by Id1 was dependent on the c-Myc expression, we examined the effect of c-Myc on Bmi-1 expression in Id1 overexpressing MCF7 cell lines. As shown in Figure 3a (right panel), the downregulation of c-Myc by the siRNA abrogated the Id1-mediated Bmi-1 upregulation as assessed by immunoblotting and reverse transcriptase-PCR. Because c-Myc can also function as a transactivator of Id proteins (Geng et al., 2010) , we checked the Id1 expression in these cell lines. However, transient knockdown of c-Myc was not sufficient for alteration of the constitutive overexpression of Id1 ( Figure 3a ). To further investigate whether Id1 affected Bmi-1 transcription activity through the regulation of c-Myc, we cloned the Bmi-1 promoter that contained an E-box mutant with a single nucleotide alteration of the c-Myc-binding site into the pGL3 luciferase reporter vector and then carried out the luciferase assay. As shown in Figure 3b , the activity of Bmi-1 promoter mutant in Id1 overexpressing MCF7 cells was as low as in the control (lane 5 versus 6), suggesting that Id1 regulated Bmi-1 transcription through c-Myc binding to (Id1si) in 2.5% serum conditions for 72 h. A volume of 50 mg cell lysates and total RNA were analyzed for expression of the indicated genes by western blot analysis and reverse transcriptase-PCR, respectively. b-Actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (b) MDA-MB-231 cells were infected with retrovirus encoding empty vector (con) or Id-1 antisense (Id1 AS) and were cultured in 10% serum conditions. Each cell lysate and total RNA was analyzed for expression of the indicated genes by western blot analysis and reverse transcriptase-PCR, respectively. All experiments were performed in triplicate.
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T Qian et al the E-box in its promoter. Recently, Guo et al. (2007) reported that Mel-18 regulated Bmi-1 expression via downregulation of c-Myc. To examine whether upregulation of c-Myc and Bmi-1 was because of the alteration of Mel-18 expression by Id1, Mel-18 was artificially overexpressed in MCF7 Id1 cell lines and both protein and mRNA levels of c-Myc and Bmi-1 were consequently downregulated ( Figure 3c ). Moreover, the Bmi-1 promoter activity was reduced by Mel-18 expression recovery ( Figure 3d , lane 6). Taken together, these data suggest that Id1 enhances c-Mycmediated activation of Bmi-1 transcription through inhibition of Mel-18.
Id1 induces geminin and histone H2A ubiquitination through RING1b E3 ligase activation It has been demonstrated that the RING finger protein Bmi-1 binds with E3 ligase RING1b to enhance its E3 ligase activity and thus induces histone H2A ubiquitination at lysine 119 (Li et al., 2006) . Therefore, we asked whether Id1 has the ability to enhance RING1b E3 ligase activity through upregulation of Bmi-1. We examined the level of histone H2A ubiquitination by western blot and found that Id1 overexpression resulted in accumulation of histone H2A ubiquitination ( Figure 4a , left panel). Our results also confirmed that Id1 overexpression had no effect on tri-methylation of histone H3 lysine 27. We then investigated the expression of geminin, a target of RING1b E3 ubiquitin ligase, (Ohtsubo et al., 2008) and found that overexpression of Id1 in MCF7 cells downregulated geminin at the protein level but not the mRNA level. Similarly, Id1 knockdown led to a reduction of histone H2A ubiquitination and upregulation of geminin expression in both MCF7 and MDA-MB-231 cell lines (Figure 4a , left and right panels). The protein synthesis inhibitor cycloheximide was then used to examine whether Id1 affected protein degradation of geminin. On cycloheximide treatment, geminin stability was more rapidly decreased in Id1 overexpressing MCF7 cells and its expression absolutely disappeared after 1 h of the treatment (Figure 4b , left panel). The proteasome inhibitor MG132 led to significantly restored geminin expression (Figure 4b , right panel). Moreover, the in vivo ubiquitination assay showed an increased detection of endogenously ubiquitinated geminin (Figure 4c ), suggesting proteasomal degradation of geminin by Id1. To further study whether Id1-induced geminin degradation via activation of RING1b E3 ligase, we overexpressed RING1b wild type or RING domain mutant plasmid, RNF2 C51W/ C54S, in the MCF7 Id1 cell line and found that the double mutation RNF2 C51W/C54S recovered geminin expression ( Figure 4d ). These data indicate that Id1 induces degradation of geminin via the ubiquitinproteasome pathway by enhancing the E3 ligase activity of RING1b. We also showed that Id1-mediated activation of RING1b E3 ligase is dependent on Bmi-1 expression, because transient knockdown of Bmi-1 expression by siRNA recovered the geminin expression and abolished the histone H2A ubiquitination in Id1 overexpressing MCF7 cells (Figure 4e ). Taken together, these data indicate that Id1 regulates the ubiquitination of geminin and histone H2A through the activation of RING1b E3 ligase mediated by Bmi-1.
Discussion
In this study, we associated the functions of Id1 with PcG protein-mediated epigenetics. Our data indicated that activation of the Akt pathway by Id1 decreased the expression of Mel-18 and consequently upregulated the transcription of its target gene c-Myc. This led to activation of Bmi-1 transcription through c-Myc binding to its E-box in the promoter. Upregulation of Bmi-1 transcription then enhanced the activity of E3 ligase RING1b, resulting in accelerated histone H2A ubiquitination and ubiquitin/proteasome-mediated degradation of geminin. In this study, we provided the first evidence that Id1 could regulate epigenetic modification and enhance PRC1 complex-mediated RING1b E3 ligase activity through the Akt pathway ( Figure 5 ). Members of PRC complexes have been implicated as epigenetic gene silencers and have a positive role in the regulation of cell proliferation and neoplastic development through epigenetic modification (Lund and van Lohuizen, 2004) . It is also established that PcG proteins are correlated with tumorigenesis (Sparmann and van Lohuizen, 2006) . Id1, well known as a putative oncogene, has been widely reported to promote cell proliferation and cell cycle progression, and is also implicated in the regulation of cell survival, metastasis, invasion and angiogenesis (Ling et al., 2006) . Over- Figure 1a were analyzed for expression of the indicated genes by western blot analysis and reverse transcriptase-PCR, respectively. (b) Control (neo) and Id1 over-expressing (Id1) cells were 1% serum treated for 42 h, and additionally cultured with the same medium containing LY294002 (40 mM) or dimethyl sulfoxide for 6 h. Each cell lysate was analyzed for the expression of the indicated proteins by western blot analysis. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Regulation of PRC1 complex by Id1 T Qian et al expression of Id1 has been detected in various types of human cancer cell lines. Loss of histone deacetylases-1 was reported to contribute to the derepression of Id1 expression in human breast cancer cells (Singh et al., 2002) . Besides this, few studies have reported that Id1 is related to epigenetic transcriptional regulation. Therefore, our data provide the new insight that Id1 was involved in PRC1 complex-mediated gene silencing through the Akt pathway. Several studies have suggested that Id1 functions diversely through the Akt pathway. In this study, we disclosed that Id1 positively regulated the activation of the PI3K/Akt signaling pathway and consequently affected the expression of Mel-18 and Bmi-1, both of which belong to the PRC1 complex. Mel-18 has been proposed to function as a tumor suppressor (Kanno et al., 1995) and its expression was reported to be decreased in human breast cancer cell lines (Matsuo et al., 2002) . This phenomenon may be explained by our finding that expression of Mel-18 was suppressed by Id1, which was identified as being overexpressed in human cancer cell lines. However, we could not provide the mechanism through which the PI3K/Akt signaling pathway negatively mediated Mel-18 regulation in this study. Several reports have indicated that Akt is involved in the degradation of tumor suppressors through ubiquitination. As demonstrated by Tang et al. (2007) , activation of Aktphosphorylated merlin resulted in the degradation of Figure 1a (left panel), or transfected with c-Myc siRNA (Myc si) or scrambled siRNA (con) for 48 h under 1% serum conditions (right panel). Each cell lysate and total RNA was analyzed for expression of the indicated genes by western blot analysis and reverse transcriptase-PCR, respectively. (b) Cells were transiently transfected with pGL3-basic vector (pGL3-basic), pGL3-Bmi-1 promoter wild type (pGL3-Bmi-1 prWT), or pGL3-Bmi-1 promoter mutant (pGL3-Bmi-1 pr^E-box) for 48 h under 1% serum conditions and then the promoter activity was measured as described in the Materials and methods. The experiment was performed in triplicate. *Po0.01, statistically significant increase compared with lane 3 (Student's t-test). (c) To restore Mel-18 expression, Id-1 overexpressing MCF7 cells were infected with retrovirus encoding empty vector (con) or Mel-18 construct (Mel-18) as described in the Materials and methods, and the cells were treated with 1% serum for 48 h. 50 mg cell lysates and total RNA were analyzed for expression of the indicated genes by western blot analysis and reverse transcriptase-PCR, respectively. (d) Cells were transiently transfected with pGL3-basic, pGL3-Bmi-1 prWT, or pGL3-Bmi-1 pr^E-box for 48 h in 1% serum, and then the promoter activity was measured as described in the Materials and methods. Each experiment was performed in triplicate. ww Po0.01, statistically significant decrease compared with lane 5 (Student's t-test). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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T Qian et al merlin via ubiquitination. In addition to direct binding with the targets, activated Akt was also suggested to promote MDM2-mediated ubiquitination, leading to degradation of p53 (Zhou et al., 2001) . Thus it is possible that Akt induces degradation of Mel-18 through ubiquitination, and we are conducting further studies to explore the mechanism by which Akt induces Mel-18 degradation. Figure 1a and 50 mg cell lysates and total RNA were analyzed for expression of the indicated genes by western blot analysis and reverse transcriptase-PCR, respectively. (b) The 1% serum-treated cells were cultured with cycloheximide (CHX, 10 mM) for the indicated period and harvested simultaneously after 48 h. The indicated proteins were examined by western blot analysis. The 1% serum-treated cells were cultured with MG132 (1 mM) and the same volume of ethanol for 0.5 h and harvested simultaneously after 48 h. The indicated proteins were examined by western blot analysis. (c) Cells were treated with 2 mM MG132 in 1% serum media for 48 h. The amount of ubiquitinated endogenous geminin was measured by in vivo ubiquitination assay as described in the Materials and methods. (d) To obtain the expression of the RING1b mutant with a mutation in the RING finger domain, Id-1 overexpressing MCF7 cells were infected with retrovirus encoding empty vector (con), RNF2 wild-type construct (WT), or RNF2 C51W/C54S mutant (MU) and 1% serum treated for 48 h. A volume of 50 mg cell lysates and total RNA were analyzed for expression of the indicated genes by western blot analysis. (e) To reduce Bmi-1 expression, Id1 overexpressing cells were transfected with Bmi-1 siRNA (Bmi si) or scrambled siRNA (con) for 48 h in 1% serum medium. The cell lysates were used for western blot analysis. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
It is important that
Regulation of PRC1 complex by Id1 T Qian et al et al., 2010). However, c-Myc could not alter the expression of Id proteins under constitutive Id-1 overexpression conditions, implying that Id1 overexpression leads to the disruption of regulation of Id proteins by c-Myc. This result suggests that constitutive overexpression of Id-1 may constantly activate the c-Myc oncogene, and consequently enhance cell proliferation and transformation, and leads to cancer. Therefore, it could be suggested that activation of c-Myc is partly attributed to the oncogenic function of Id1.
In our investigations, Id1 was suggested to induce RING1b E3 ligase activity through a PRC1 complex, Bmi-1/ Mel-18. Although both Mel-18 and Bmi-1 have been suggested as regulators of RING1b E3 ligase activity, it is unclear which is more critical for RING1b E3 ligase activity. Mel-18 phosphorylation is required for RING1b-mediated H2A ubiquitination (Elderkin et al., 2007) , but it seems that Mel-18 expression mainly exists in its total form rather than its phosphorylated form. Furthermore, recent studies have demonstrated that loss of Mel-18 expression leads to upregulation of Bmi-1 (Guo et al., 2007; Lee et al., 2008) . Therefore, it is suggested that the effect of Id-1 on RING1b activity may be more powerfully mediated through upregulation of Bmi-1 rather than Mel-18 phosphorylation. RING1b, a well-known E3 liagase, was reported to promote cell proliferation in hematopoietic cells (Cales et al., 2008) and maintain an undifferentiated state of mouse embryonic stem cells (van der Stoop et al., 2008) . Moreover, deficiency of RING1b resulted in gastrulation arrest and cell cycle inhibition (Voncken et al., 2003) . PRC1 complex including RING1b as the central subunit has the ability to mediate histone H2A ubiquitination at lysine 119 to maintain transcription repression of target genes, such as Hox genes (Cao et al., 2005; Li et al., 2006; Elderkin et al., 2007) . Our results showed that Id1 could enhance histone H2A ubiquitination at lysine 119 (Figure 4) . Therefore, it may be suggested that, Id1 could be involved in the suppression of Hox genes and regulation of development. In addition, we also found that the degradation of geminin, an important developmental regulatory molecule (Kroll, 2007) , was mediated by Id1 through the PRC1 complexmediated proteasomal pathway (Figure 4) . Several target genes of the ubiquitin-proteasome pathway have been identified to be involved in cell cycle control (Bernardi et al., 2000; Zhao et al., 2000; Hattori et al., 2003) . Taken together, our results suggested that Id1 may regulate tumor cell proliferation and cell cycle progression through its effect on the PRC1 complex.
PcG proteins, especially Bmi-1, have been demonstrated to participate in cancer and the self-renewal of multiple types of stem cells. A large number of surveys implicate Bmi-1 as a stem cell marker. It has been reported that Bmi-1 has essential roles in regulating the generation of self-renewing adult haematopoietic stem cells and the proliferative activity of both normal and leukemic stem cells (Lessard and Sauvageau, 2003; Park et al., 2003) . Liu et al. (2006) argued that Bmi-1 has important roles in regulating self-renewal of normal and tumorigenic human mammary stem cells that existed in breast cancers. As shown in our investigation, the transcription of Bmi-1 was significantly upregulated by Id1 (Figure 3) , suggesting that Id1 may contribute to Figure 5 Proposed model for regulation of RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 pathway by Id1. Id1 activates the phosphoinositide-3 kinase (PI3K)/Akt pathways. The enhanced Akt phosphorylation leads to Mel-18 degradation, which then results in activation of c-Myc and Bmi-1 transcription in the nucleus. Together with the CBX family, the increased Bmi-1 protein then binds to RING1b to promote its E3 ligase activity. The increased RING1b E3 ligase activity promotes histone H2A ubiquitination at lysine 119 leading to silence of target genes, such as Hox genes, and enhances the proteasomal degradation of geminin. Thus, Id1 may be involved in PcG complex-mediated biological effects such as cell proliferation and differentiation, and also in stem cell regulation.
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T Qian et al stemness of cancer stem cells. It is known that geminin is not detected in the G1 phase and increases during progression into the S phase (McGarry and Kirschner, 1998) . Geminin was supposed to have a crucial role in supporting stem cells by regulating cellular proliferation, differentiation and further genome stability (Ohtsubo et al., 2008) . Another study regarded geminin as a critical regulator for maintaining an undifferentiated state through the regulation of a chromatinremodeling complex (Seo et al., 2005) . In this study, we showed that the overexpression of Id1 contributed to the proteasomal degradation of geminin through upregulation of RING1b E3 ligase activity (Figure 4 ). These findings implied that Id1 may be a novel stem cell regulator and has a crucial role in regulating selfrenewal of malignant human stem cells. In summary, our data correlated Id1 with epigenetic modification-mediated regulation of tumorigenesis. We suggested that the Id1-Akt-Mel-18-c-Myc-Bmi-1 pathway was a novel mechanism by which Id1 regulated tumor cell proliferation and cell cycle progression. Because Bmi-1 and geminin that were modulated by Id1 were associated with self-renewal of human stem cells, we speculated that Id1 may be a stem cell regulator.
Materials and methods
Cell culture and drug treatment MCF7 and MDA-MB-231 cells were maintained in Dulbecco's modified essential medium, (WelGene, Daegu, Korea), supplemented with 10% fetal bovine serum (WelGene) and 1% penicillin/streptomysin (WelGene). For drug treatment, cells were incubated in 1% serum medium, then treated for the indicated period and harvested simultaneously after 48 h. Drugs were used as follows: LY294002 from Sigma-Aldrich (St Louis, MO, USA), diluted in dimethyl sulfoxide cycloheximide and MG132 from Sigma-Aldrich diluted in ethanol.
Transfection and retroviral infection pCI-neo empty vector or pCI-neo-Id1-HA stably transfected MCF7 cells were generated as previously described (Kim et al., 2007) , and maintained in the above medium supplemented with 0.1 mg/ml G418 sulfate (Sigma-Aldrich). Id1 stably overexpressing MCF7 cells infected with retrovirus-encoding Mel-18 complimentary DNA were generated as described earlier to enforce Mel-18 overexpression . Cells were cultured in 1% serum medium for 48 h to suppress endogenous Id1 expression of the estrogen-receptor positive MCF7 cell line in all of the experiments as previously described (Kim et al., 2007) . RNF2 wild type and C51W/C54S mutant constructs were kindly provided by Seongman Kang (Korea Universty, Seoul, Korea). Both complimentary DNAs were cut with NotI and XhoI reaction enzymes and subcloned into pEGFPBsd-IRES3-CL retroviral vector, and then retrovirus encoding either RNF2 wild type or mutant was generated as described above. siRNA targeting Id1 was purchased from Dharmacon (Chicago, IL, USA) and was then transfected into MCF7 cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in 2.5% serum medium. MCF7 cells transiently transfected with Id1 siRNA were harvested after 72 h. c-Myc siRNA and Bmi-1 siRNA were purchased from Bioneer (Seoul, Korea) and transfected into Id1 overexpressing MCF7 cells with Lipofectamine 2000 under 1% serum conditions for 48 h.
MDA-MB-231 cells infected with pEGFPBsd-IRES3-CL empty vector or retroviral vector containing Id1 antisense complimentary DNA were generated as previously described , then stable transfectant clones were selected by 10 mg/ml blasticidin S (Invitrogen) and maintained in the above medium supplemented with 1 mg/ml blasticidin S.
Immunoblotting Cells were lysed in radioimmunoprecipitation assay buffer supplemented with protease inhibitors (Complete, Mini, EDTA-free; Roche Applied Science; Indianapolis, IN, USA) and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich) and centrifuged to obtain the cleared lysates. Immunoblotting was then carried out as described previously . Antibodies against Id1 (C-20), Id2 (C-20), Id3 (C-20), Mel-18 (H-115), YY1 (H-10), RING1b (N-32), EED (H300) and geminin (FL209) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against Ser473 phospho-Akt, total Akt, Bmi-1, c-Myc, EZH2 (AC22), histone H3 and ubiquitin (P4D1) were from Cell Signaling Technology (Beverly, MA, USA). Antibodies against ubiquityl-histone H2A (E6C5), histone H2A (acidic patch) and trimethyl-histone H3 (Lys27) were from Upstate Biotechnology (Lake Placid, NY, USA). Antibody against b-actin was from Sigma-Aldrich. The western blot bands of Mel-18 and Bmi-1 densities were determined using AlphaEase FC Software (AlphaInnotech, Inc., San Leandro, CA, USA).
Reverse transcription-PCR Total RNA extraction from cells using TRIZOL Reagent (Invitrogen) and reverse transcription-PCR were carried out as previously described (Kim et al., 2007) . Promoter assay Bmi-1 promoter-luciferase reporter construct pGL3-Bmi-1-PrWT and a mutation containing construct pGL3-Bmi-1-PrMut were generated as previously described (Guo et al., 2007) . Cells were seeded at 1.2 Â 10 5 cells per well of a 12-well plate the day before transfection and co-ransfected with the reporter construct and a b-galactosidase expression vector using FuGENE 6 (Roche Diagnostics Corp., Indianapolis, IN, USA). Cells were incubated in the transfection medium for 24 h and then in 1% serum medium for an additional 48 h. Cells were harvested and lysed by reporter lysis buffer (Luciferase Assay System with Reporter Lysis Buffer; Promega, Madison, WI, USA), and luciferase activities were measured by a Microplate Luminometer (Berthold, Oak Ridge, TN, USA).
